Menu
Recruiting NCT06815666

BAL Fluid Biomarkers in Sarcoma

Phase II Interventional Soft Tissue Sarcoma (STS) Bronchoalveolar Lavage (BAL) Bronchoalveolar Lavage Fluid

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Bronchoscopy & Metastasectomy.
Who it may be relevant to
Registry conditions: Soft Tissue Sarcoma (STS), Bronchoalveolar Lavage (BAL), Bronchoalveolar Lavage Fluid. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Prospective Study of Biomarkers Derived From Bronchoalveolar Lavage Fluid to Predict Outcomes in Soft-Tissue Sarcomas

Overview

This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.

Interventions

  • Procedure Bronchoscopy & Metastasectomy
    Routine bronchoscopy and standard of care metastasectomy

Primary outcome measures

  • Identification of NET-related inflammatory biomarkers using BALF and TA diagnostic tools [Time frame: 2 years]
  • Quantification of NET-related inflammatory biomarkers using BALF and TA diagnostic tool [Time frame: 2 years]
  • Correlation of NET-related inflammatory markers using BALF and TA diagnostic tool with the extent of metastatic dissemination [Time frame: 2 years]
Secondary outcome measures (3)
  • Analysis of NET-related inflammatory biomarkers using BALF and TA diagnostic tool [Time frame: 2 years]
  • Correlation between NET-related inflammatory biomarkers using BALF and TA diagnostic tool [Time frame: 2 years]
  • NET-related inflammatory biomarker differences for BALF and TA diagnostic tools [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years
  • Ability to understand and willingness to sign a written informed consent document
  • Diagnosed with soft tissue sarcoma
  • Undergoing resection of lung lesion as part of standard care

Exclusion criteria

1\. History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Canada · 1 center
  • Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network — Toronto

Identifiers

NCT: NCT06815666 · 24-5871

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗